Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study
In: Leukemia Research, Jg. 37 (2013-02-01), Heft 2, S. 162-168
academicJournal
Zugriff:
Abstract: EXELS is an ongoing phase IV non-interventional study; 3643 high-risk patients with essential thrombocythemia (ET) were recruited across 13 European countries. We report patient characteristics and cytoreductive treatment patterns of ET across Europe. Hydroxycarbamide (HC; 64.3%) and anagrelide (22.0%) were the two main cytoreductive treatments prescribed. The proportions of patients taking either HC or anagrelide varied across countries, as did the number of patients receiving anti-aggregatory therapy in addition to cytoreductive treatment. This real-world evidence demonstrates that, generally, treatment patterns of ET across Europe adhere to expert recommendations, with some notable variations between countries. [Copyright &y& Elsevier]
Titel: |
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study
|
---|---|
Autor/in / Beteiligte Person: | Besses, Carlos ; Kiladjian, Jean-Jacques ; Griesshammer, Martin ; Gugliotta, Luigi ; Harrison, Claire ; Coll, Ruth ; Smith, Jonathan ; Abhyankar, Brihad ; Birgegård, Gunnar |
Zeitschrift: | Leukemia Research, Jg. 37 (2013-02-01), Heft 2, S. 162-168 |
Veröffentlichung: | 2013 |
Medientyp: | academicJournal |
ISSN: | 0145-2126 (print) |
DOI: | 10.1016/j.leukres.2012.11.004 |
Schlagwort: |
|
Sonstiges: |
|